Abstract
Renal cell cancer is fastly growing in incidence worldwide. No adjuvant therapy has been unarguably proven feasible so far, although an autologous vaccine has achieved a significant benefit. An effective agent in adjuvant therapy against renal cell cancer must achieve several goals. It should be relatively non toxic, have estabilished efficacy in the metastatic setting, and have demonstrated efficacy against the standard of care in randomized phase III trials. The development of adjuvant therapy requires the properly identification of patients at highest risk of relapse, as potential benefactors of adjuvant therapy development. Our ability to predict when and where patients will recur has much room for improvement. Therefore several models and nomograms including the most important prognostic and predictive factors have been developed. Nevertheless, during the past few years, major advances have been made concerning the metastatic setting of the disease with the arrival of new drug classes such as tyrosine kinase inhibitors and monoclonal antibodies, strongly improving overall and progression free survivals, renewing hopes on activity regarding the adjuvant therapy. Several trials are today in progress to evaluate the effectiveness of antiangiogenic agents in this area. An overall review of the completed and upcoming trials and patents shall be discussed here.
Keywords: Renal cell cancer, adjuvant therapy, immunotherapy, vaccine, new drugs
Recent Patents on Anti-Cancer Drug Discovery
Title: Renal Cell Cancer: State of the Art in Adjuvant Therapy
Volume: 5 Issue: 3
Author(s): Sebastiano Buti and Rodrigo Kraft Rovere
Affiliation:
Keywords: Renal cell cancer, adjuvant therapy, immunotherapy, vaccine, new drugs
Abstract: Renal cell cancer is fastly growing in incidence worldwide. No adjuvant therapy has been unarguably proven feasible so far, although an autologous vaccine has achieved a significant benefit. An effective agent in adjuvant therapy against renal cell cancer must achieve several goals. It should be relatively non toxic, have estabilished efficacy in the metastatic setting, and have demonstrated efficacy against the standard of care in randomized phase III trials. The development of adjuvant therapy requires the properly identification of patients at highest risk of relapse, as potential benefactors of adjuvant therapy development. Our ability to predict when and where patients will recur has much room for improvement. Therefore several models and nomograms including the most important prognostic and predictive factors have been developed. Nevertheless, during the past few years, major advances have been made concerning the metastatic setting of the disease with the arrival of new drug classes such as tyrosine kinase inhibitors and monoclonal antibodies, strongly improving overall and progression free survivals, renewing hopes on activity regarding the adjuvant therapy. Several trials are today in progress to evaluate the effectiveness of antiangiogenic agents in this area. An overall review of the completed and upcoming trials and patents shall be discussed here.
Export Options
About this article
Cite this article as:
Buti Sebastiano and Kraft Rovere Rodrigo, Renal Cell Cancer: State of the Art in Adjuvant Therapy, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (3) . https://dx.doi.org/10.2174/157489210791760544
DOI https://dx.doi.org/10.2174/157489210791760544 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets Editorial [Hot Topic: The Application of Systems Biology and Bioinformatics Methods in Proteomics, Transcriptomics and Metabolomics (PART II)]
Protein & Peptide Letters The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine
Current Drug Targets Design, Synthesis and Structure-Activity Relationship Studies of Novel 4 (1-adamantyl) Phenyl Analogues as HIF-1α Inhibitors
Medicinal Chemistry Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets CatbNet: A Multi Network Analyzer for Comparing and Analyzing the Topology of Biological Networks
Current Genomics Carbohydrate Based Blood Antigens in Cancer: Current Status and Future Perspectives
Letters in Drug Design & Discovery Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy
Current Pharmaceutical Design Analysis of Current Antifungal Agents and Their Targets within the Pneumocystis carinii Genome
Current Drug Targets Chemotherapy for Prostate Cancer
Current Pharmaceutical Design Anthracyclines: Selected New Developments
Current Medicinal Chemistry - Anti-Cancer Agents Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer
Anti-Cancer Agents in Medicinal Chemistry DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Novel Insights and Therapeutical Applications in the Field of Inhibitors of COX-2
Current Medicinal Chemistry Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets
Current Protein & Peptide Science Gallic Acid-Phospholipid Complex: Drug Incorporation and Physicochemical Characterization
Letters in Drug Design & Discovery Progress in Gene Delivery by Cationic Lipids : Guanidinium-Cholesterol-Based Systems as an Example
Current Drug Targets Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment
Current Drug Delivery Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design